Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Impact of Social Determinants of Health and Geographic Location on Real-World Outcomes in AML Patients Undergoing Low-Intensity Chemotherapy

Valerie Tran, Gordon Smilnak, Nandan Srinivasa, Firas El Chaer, Michael Keng, Daniel Reed

Blood (2024) 144 (Supplement 1): 7904.

https://doi.org/10.1182/blood-2024-201720

Published: 2024

Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Blood (2024) 144 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2024-200999

Published: 2024

Journal Articles

Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia

Natalie Pham, Jeffrey Lantz, Jr., Caroline Jones, Debamita Kundu, Nicholas McCann, Firas El Chaer, Daniel Reed, Michael Keng

Blood (2024) 144 (Supplement 1): 791.

https://doi.org/10.1182/blood-2024-211962

Published: 2024

Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Blood (2024) 144 (Supplement 1): 655.

https://doi.org/10.1182/blood-2024-200312

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2024-194922

Published: 2024

Journal Articles

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 424.

https://doi.org/10.1182/blood-2023-186822

Published: 2023

Journal Articles

Persistence of FLT3 -TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission

Blood (2023) 142 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2023-180121

Published: 2023

Journal Articles

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2023-186376

Published: 2023

Journal Articles

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

John Mascarenhas, Tsewang Tashi, Firas El Chaer, Victor Priego, Oleh Zagrijtschuk, Albert Qin, Jewell Jessup, Craig Zimmerman, Ray Urbanski, Lucia Masarova

Blood (2023) 142 (Supplement 1): 6444.

https://doi.org/10.1182/blood-2023-189912

Published: 2023

Journal Articles

Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2023-178839

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

Jeffrey Lantz, Jr., Natalie Pham, Caroline Jones, Debamita Kundu, Nicholas McCann, Firas El Chaer, Daniel Reed, Michael Keng

Blood (2023) 142 (Supplement 1): 7436.

https://doi.org/10.1182/blood-2023-190176

Published: 2023

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

How I treat AML incorporating the updated classifications and guidelines

Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan

Blood (2023) 141 (23): 2813–2823.

https://doi.org/10.1182/blood.2022017808

Published: 2023

Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 594–595.

https://doi.org/10.1182/blood-2022-159086

Published: 2022

Journal Articles

How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies

Firas El Chaer, Jeffery J. Auletta, Roy F. Chemaly

Blood (2022) 140 (7): 673–684.

https://doi.org/10.1182/blood.2022016089

Published: 2022

Journal Articles

Multidisciplinary Provider Insights to Promote Adoption of Bispecific Antibodies to Treat Cancer in the Community

Limaya Atembina, Leigh Boehmer, Kelly Terrell, Rima Koka, Murali Janakiram, Axel Grothey, Amy L Morris, Srinivas Devarakonda, Barbara Rogers, Ronan Kelly, Jesus Berdeja, Firas El Chaer

Blood (2021) 138 (Supplement 1): 4033.

https://doi.org/10.1182/blood-2021-153794

Published: 2021

Journal Articles

Reducing Length of Stay for Patients with Acute Myeloid Leukemia Receiving Inpatient High-Dose Cytarabine Consolidation Chemotherapy

David O Riley, Caroline Jones, Amy L Morris, Jeremy M Sen, Nicholas J Schmidt, Jr., Alana Ferrari, Joshua Humphrey, Jenna VanHoose, Jenna Schlefman, Firas El Chaer, Michael K Keng

Blood (2021) 138 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2021-148202

Published: 2021

Journal Articles

Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting

Monique D. Dawkins, EdD, Firas El Chaer, MD, Leigh Boehmer, PharmD, Ashkan Emadi, MD, Elias Jabbour, MD, Jeffrey Kendall, PsyD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Sandra Kurtin, PhD, ANP-C, AOCN, Mohamed Hersi, PharmD, Meredith Barnhart, LCSW-R

Blood (2019) 134 (Supplement_1): 5834.

https://doi.org/10.1182/blood-2019-123461

Published: 2019

NARROW

Impact of Social Determinants of Health and Geographic Location on Real-World Outcomes in AML Patients Undergoing Low-Intensity Chemotherapy

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Persistence of FLT3 -TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

How I treat AML incorporating the updated classifications and guidelines

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies

Multidisciplinary Provider Insights to Promote Adoption of Bispecific Antibodies to Treat Cancer in the Community

Reducing Length of Stay for Patients with Acute Myeloid Leukemia Receiving Inpatient High-Dose Cytarabine Consolidation Chemotherapy

Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only